Objective: To evaluate the postoperative value of serum carbohydrate antigen 21-1 (CA211) and Insulin Growth Factor-1 (IGF-1) in the treatment of patients with non-small cell lung cancer.
Methods: From May 2015 to May 2017, 52 patients with Non-Small Cell Lung Cancer (NSCLC) were collected in our hospital as the study objects. They were regarded as study group (n=52) and another 52 healthy patients were selected as control group. The level of CA211 and IGF-1 was measured before and after treatment in the two groups. The measurements were compared both in and between different groups.
Results: The results showed that both the serum level of CA211 and IGF-1 in patients from the study group were significantly higher than those in the patients from the control group (P<0.05); and after treatment, the serum CA211 and IGF-1 level of patients in the study group decreased significantly comparing with the pre-treatment value (P<0.05).
Conclusion: There is a correlation between the level of serum CA211 and IGF-1 and the progression of non-small cell lung cancer, thus they can serve as indicators to evaluate the recovery of patients after treatment.